Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...
Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Karen Peterson was diagnosed with stage 1 ...
What’s been overlooked is that the FDA already has the power to fix this. Without new legislation, pilot programs, or years ...
BALTIMORE, MD., November 6, 2025--Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early phase ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
Clinical development accelerator Quotient Sciences and CRO Lindus Health are joining forces to create a streamlined process for clients to advance from first-in-human (FIH) up to pivotal trials. The ...
The Company expects to complete full enrollment by early 2026 and is moving its timelines up three to six months, cutting its anticipated capital needs by $10-$15 million White Bear Lake, ...
NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results